Comparative Pharmacology
Head-to-head clinical analysis: ALLEGRA HIVES versus DISOMER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALLEGRA HIVES versus DISOMER.
ALLEGRA HIVES vs DISOMER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fexofenadine is a non-sedating antihistamine (H1-receptor antagonist) that selectively inhibits peripheral H1 receptors, reducing histamine-mediated symptoms such as pruritus, urticaria, and vasodilation. It does not cross the blood-brain barrier significantly, minimizing CNS effects.
Selective dopamine D2 receptor antagonist; also blocks alpha-1 adrenergic, histamine H1, and muscarinic M1 receptors.
Fexofenadine hydrochloride 60 mg orally twice daily or 180 mg orally once daily.
Adults: 1 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 14.4 hours (range 11–17 hours). This supports once-daily dosing in most patients; however, in moderate to severe renal impairment, half-life may be prolonged (e.g., ~22 hours), necessitating dosing adjustment.
12–15 hours in adults with normal renal function; prolonged to 30–40 hours in severe renal impairment (CrCl <30 mL/min).
Fexofenadine is primarily excreted unchanged in feces (80%) and urine (11%). The remainder undergoes minimal hepatic metabolism. Renal elimination accounts for about 11% of the dose.
Renal: 80% as unchanged drug; biliary/fecal: 15% as metabolites; <5% unchanged in feces.
Category C
Category C
Antihistamine
Antihistamine